Câncer de pulmão não pequenas células metastático: heterogeneidade do tratamento na prática clínica de rotina no Brasil by Naime, Fauzia F. et al.
397
CLINICS 2007;62(4):397-404
CLINICAL SCIENCES
1Instituto Paulista de Cancerologia - Department of Clinical Oncology- São
Paulo/SP, Brazil
2Hospital AC Camargo - Department of Thoracic Surgery-São Paulo/SP, Brazil
3Hospital Amaral Carvalho de Jaú. Department of Clinical Oncology- Jaú/
SP, Brazil
4Grupo Paulista de Oncologia Integrada - Department of Clinical Oncology-
São Paulo/SP, Brazil
Email: fauzianaime@yahoo.com.br
Received for publication on January 23, 2007
Accepted for publication on March 27, 2007
METASTATIC NON-SMALL CELL LUNG CANCER IN
BRAZIL: TREATMENT HETEROGENEITY IN ROUTINE
CLINICAL PRACTICE
Fauzia F. Naime1, Riad Naim Younes2, Bruno G. Kersten3, Agnaldo Anelli4, Carlos
Augusto M. Beato3, Rogério M. Andrade1, Marcella P. Carrara1, Jefferson Luiz
Gross2
Naime FF, Younes RN, Kersten BG, Anelli A, Beato CAM, Andrade RM, Carrara MP, Gross JL. Metastatic non-small cell
lung cancer in Brazil: treatment heterogeneity in routine clinical practice. Clinics. 2007;62(4):397-404.
ABSTRACT: Lung cancer is one of the main causes of cancer related deaths. Approximately three quarters of these tumors are
non-small cell carcinomas. When diagnosed the majority of patients show the disease locally advanced or metastatic. The
chemotherapy is the chosen therapy for patients with advanced lung cancer. The majority of published studies with chemotherapy
are performed in academic centers under a strict control of research protocols.
PURPOSE: The aim of this study is to evaluate the usual management of metastatic NSCLC patients outside of a clinical trial
setting in three different oncologic centers in Brazil.
METHODS: This is a retrospective study of patients with metastatic non-small cell lung cancer admitted for treatment in three
different Cancer Centers in Brazil. 564 patients from Brazilian public heath system and private/health insurance system were
considered for the present study.
RESULTS: Among 564 patients in this study, 335 (59.4%) received chemotherapy. For all patients, 47 different regimens of
chemotherapy were identified. The median follow-up time was eight months and the overall median survival of all patient population
submitted to chemotherapy was 9.7 months.
DISCUSSION: There was a great heterogeneity in the regimens of drugs to treat metastatic NSCLC patients. The overall survival
was significantly better for patients treated with first line chemotherapy compared to patients that only received best supportive
care. Results of prospective randomized clinical trials should be carefully analyzed before transferred to the daily clinical practice.
KEY WORDS: Lung Cancer. Non Small Cell Lung Cancer (NSCLC). Metastases. Chemotherapy. Routine clinical practice.
INTRODUCTION
Lung cancer is the second most common cancer, and
the leading cause of cancer death in the United States of
America. There are over 160.000 new cases each year in
that country and estimated overall 5-year survival remains
at 15%. One of the reasons for this poor survival is that
39% of patients had advanced disease at diagnosis1. The
INCA (National Institute of Cancer) in Brazil estimates that
27.000 new cases of NSCLC will be diagnosed in 2006
among Brazilians2. The most common histological types
are squamous cell carcinoma, adenocarcinoma, and large
cell carcinoma. As approaches to treatment are similar,
these histological types are classified together as non-small
cell lung cancer (NSCLC), which is responsible for over
80% of all patients diagnosed with lung cancer.
There are well-established guidelines that suggest thera-
peutic approaches for non-small cell lung cancer patients3.
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Since the last decade, chemotherapy has been recommended
as the treatment of choice in order to improve quality of life
and prolong survival time for advanced disease. Recent meta-
analysis compared outcomes of platinum-based versus sin-
gle agent chemotherapy for metastatic NSCLC patients, and
showed that platinum-based doublets produced higher over-
all response rate than with single agents. Platinum-based
therapy was also associated with a 13% higher survival rate4.
Another prospective randomized study5 evaluated 1,155 eli-
gible advanced NSCLC patients to compare four different
platinum-based regimens of chemotherapy
(CDDP+Paclitaxel / CDDP+Gencitabine / CDDP+Docetaxel
/ Carboplatin+Paclitaxel). The response rate was 19%, with
a median survival time of 7.9 months. The response rate and
median survival did not differ among different regimens of
chemotherapy, although cisplatin plus gemcitabine was as-
sociated with a longer time to progression as well as with
higher toxicity. Patients with poor performance status had a
significantly lower rate of survival5.
Most of these results with chemotherapy derived from
rigid protocols that included selected patients and uniform
regimens of drugs, performed on clinical-trial settings.
However there is a paucity of studies assessing the results
of the management of metastatic NSCLC in a routine clini-
cal practice, outside of a controlled clinical trial setting6 .
The aim of this study is to evaluate the usual manage-
ment of metastatic NSCLC patients outside of a clinical trial
setting in three different oncologic centers in Brazil.
PATIENTS AND METHODS
This is a retrospective study of patients with advanced
non-small cell lung cancer admitted for treatment in three
different Cancer Centers in Brazil: Hospital do Cancer A
C Camargo (HCACC), Sao Paulo; Hospital Amaral
Carvalho (HAC), Jau; and Instituto Paulista de
Cancerologia (IPC), Sao Paulo. Clinical data were reviewed
in the records of these patients from 1990 to 2003. The fol-
lowing criteria were considered to include patients: cyto-
logical or histological diagnosis of non-small cell lung can-
cer; stage IV (central nervous system metastases were in-
cluded); patients admitted and considered for oncologic
treatment according to clinical practice of each institution.
Moreover, no patient should have been included in research
protocol for treatment.
According to these inclusion criteria, 564 patients were
considered for the present study. The following clinical data
were obtained by review of the records: age, gender, per-
formance status, site of metastases, weight loss, histologi-
cal type, chemotherapy regimens and status at last follow-
up. The performance status was determined by ECOG
(Eastern Cooperative Oncology Group)7 index, according
to clinical data available in the records. Classification of
clinical staging was obtained from the records, based on
clinical notes or reports of imaging exams (chest, upper ab-
domen and brain CT, and bone scan). First-line chemo-
therapy was defined as the first chemotherapeutic approach
administered to the patient. According to the coverage of
treatment costs, patients were classified in to two groups:
Brazilian public heath system and private/health insurance
system.
Status of last follow-up was classified as alive without
disease, alive with disease, dead from cancer, dead from
other causes, and patients who did not return to institution
for a period exceeding twice the interval suggested by the
assistant physician. Such patients were defined as lost to
follow-up.
Statistical analysis: the method of Kaplan-Meier was
used to determine actuarial survival8. Differences in sur-
vival were determined by Breslow and log rank analysis.
Overall survival time was defined as the interval between
initial diagnosis of NSCLC at each center and the date of
last consultation or until death. All statistical analyses were
performed with SPSS 10.0 software. The value of p ≤ 0.05
was defined as significant.
RESULTS
The distribution of 564 patients included in the present
study according the different oncologic centers was as fol-
low: 39 (7%) from Instituto Paulista de Oncologia (IPC);
177 (31.3%) from Hospital Amaral Carvalho (HAC), and
348 (61.7%) from Hospital do Cancer A C Camargo
(HCACC).
The majority of patients included in the present study
were male (71.5%) in the sixth to seventh decades of life
(65.1%). The most common site of metastasis was bone
(32.8%), and adenocarcinoma was the predominant histo-
logic type (52.8%). The characteristics of all patients are
showed on Table 1.
Among 564 patients in the present study, 335 (59.4%)
received chemotherapy; the reasons for not treating 229
(40.6%) patients were not clearly stated in the records of
the patients included in this retrospective study.
The majority (57.3%) of treated patients received a com-
bination of two drugs, as shown in Table 2. For all patients,
47 different regimens of chemotherapy were identified.
Cisplatin or carboplatin were the most common drugs em-
ployed, other frequent drugs are taxanes, vinca alkaloids,
gemcitabine and vinorelbine (Table 3). Because of large
heterogeneity of drug regimens identified in the present
study, we could not classify these different combinations of
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drugs in comprehensive groups of regimens, so we dis-
closed all these regimens in Appendix 1. The median
number of cycles was four, ranging from one to 13. The
costs of chemotherapy were paid by Brazilian public health
system in 49.6%, and by private/health insurance system
in 50.4% of the patients.
The median follow-up time was eight months, and sta-
tus at last information were as follow: alive without dis-
ease: two (0.3%) patients; alive with disease: 32 (5.6%) pa-
tients; dead from cancer: 415 (73.6%) patients; dead from
other causes: 6 (1.1%) patients, and lost of follow-up: 109
(19.4%).
Median overall survival was 8.3 months (CI 95%: 7.5
– 9.2 months), and overall one-year survival was 37% (Fig-
ure 1). The overall survival was significantly better for pa-
tients treated with first line chemotherapy compared to pa-
tients that only received best supportive care (Figure 2).
DISCUSSION
Although metastatic lung cancer is associated with a dis-
mal prognosis, systemic treatment can result in improved
survival and better quality of life. In the past, the chemo-
therapy agents more widely used for the tretament of ad-
vanced NSCLC were cisplatin, mitomycin, vinblastine and
Table 1 – Basic characteristics of patients.
Patients profiles n %
Age (years)
d•50 94 16.7
51-70 367 65.1
> 71 103 18.2
Gender
Male 403 71.5
Female 161 28.5
Performance status (ECOG)
0 18 3.2
1 215 38.1
2 182 32.3
3 70 12.4
No data 79 14.0
Metastases
Bone 185 32.8
Lung 170 30.1
Central Nervous System 140 24.8
Liver 50 8.9
Adrenal 19 3.4
Weight loss
None 77 13.7
< 10% 65 11.5
> 10% 181 32.1
No described 241 42.7
Histology
Adenocarcinoma 298 52.8
Squamous cells carcinoma 176 31.2
Large cells carcinoma 90 16.0
Total 564 100
NA: not available.
Table 2 – Characteristics of chemotherapy.
Number of drugs No %
One 33 9.9
Two 192 57.3
Three 110 32.8
Total 335 100
Table 3 – Drugs used in different regimens of chemotherapy.
Drugs N %
Cisplatin / Carboplatin 280 83.5
Taxanes 64 19
Vinca alkaloids 60 18
Gencitabine 53 15.8
Vinorelbine 45 13.4
Others 225 67.1
Figure 2 – Overall survival according to treatment of metastatic NSCLC
patients (p<0.001 log-rank and Breslow).
Figure 1 – Overall survival for all patients included in the study.
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etoposide. As single agents, they usually result in response
rates varying between 15% and 25%9. Combination regi-
mens included cisplatin plus vinblastine, cisplatin plus
etoposide, cisplatin plus vindesine and cisplatin plus vin-
blastine plus mitomycin (MVP), with response rates rang-
ing from 15% to 30%, and one-year overall survival from
20% to 30%10,11. In the last 12 years, new and more effec-
tive chemotherapeutic agents, including paclitaxel,
docetaxel, gemcitabine, vinorelbine, irinotecan and
topotecan, were introduced for the treatment of lung can-
cer. A meta-analysis of randomized trials showed that plati-
num-based chemotherapy has been shown to improve me-
dian survival by about six weeks, and survival at one year
from 5% to 15%12. Since then, platinum-based chemo-
therapy has been considered the standard of care for ad-
vanced NSCLC patients3,13. Moreover there are two other
questions regarding the approach of these patients: 1) what
is the best combination of drugs in the first-line treatment?
2) What is the optimal duration of treatment? Two recent
randomized trials compared different regimens of cisplatin
or carboplatin-based chemotherapy and disclosed that there
was no difference in response rates or survival5,14. Accord-
ing to these trials the following regimens are considered
standard of care for advanced NSCLC patients: Cisplatin/
Paclitaxel; Carboplatin/Paclitaxel; Cisplatin/Vinorelbine;
Cisplatin/Gemcitabine; Cisplatin/Docetaxel. The duration
of chemotherapy was addressed by other randomized tri-
als, and the recommendation is that the duration of first-
line chemotherapy should be brief, consisting of three to
four cycles or fewer if there is evidence of progressive dis-
ease15-17.
These recommendations for treating advanced NSCLC
patients are mainly defined through rigid protocols of
randomized trials. However few reports evaluated the man-
agement of metastatic NSCLC patients in community set-
tings. The present study was designed to investigate the
regimens and the duration of chemotherapy employed to
treat advanced NSCLC patients not included in clinical tri-
als. The three oncologic centers considered in the present
survey are reference for oncologic treatment with experi-
enced oncologists. Moreover, two (HCACC and HAC) of
these centers have established programs of residency and
fellowship in oncology, and have participated in several
clinical trials. Clearly this might not exactly reflect the ac-
tual management performed in a community setting. On the
other hand, considering that all patients are not included
in study protocols, the therapeutics approaches are deter-
mined according to individual medical decision.
There is little information about the use of chemotherapy
for advanced NSCLC patients in the community setting.
Recently, Potosky et al reported results indicating that 41%
of stage IV NSCLC patients received chemotherapy as part
of their initial treatment in a population based sample of
NSCLC patients in the United States of America, in 19966.
However, the authors did not analyze in detail the regimens
of chemotherapy that were employed. Other studies con-
firmed that the rate of patients who received chemotherapy
for metastatic NSCLC has been increasing over recent dec-
ades, and that authors have found that nonclinical factors
(age, race or ethnicity and hospital type) influenced the de-
cision making process of choosing therapeutic approach for
NSCLC patients18. In the present study we found that 59.1%
of patients received chemotherapy, but our aim was to
evaluate how they were treated rather than the population
that actually was selected for each treatment.
Considering the patients that were submitted to chemo-
therapy, we identified 47 different regimens of drugs em-
ployed as first-line treatment, in spite of randomized clini-
cal trials recommending few combinations of drugs for ad-
vanced NSCLC19. Within this heterogeneity of drug regimens
we observed that the majority of the patients received com-
binations of two drugs (57.3%), cisplatin or carboplatin was
present in 83.5% of the treated patients, and the median
number of cycles was four, as recommended by prospective
trials addressing this issue13,20. However, almost one third of
the patients received combinations of three drugs (Table 2),
and 67.1% of the patients were treated with drugs not usu-
ally employed in regimens of first-line chemotherapy (Ta-
ble 3), both in disagreement with the recommendation from
prospective trials. Moreover, some patients received 13 cy-
cles of chemotherapy while prospective trials recommended
three to four cycles. Although the majority of patients received
adequate treatment, there was a great heterogeneity in the
regimens of drugs to treat metastatic NSCLC patients in our
community–based in cohorts of patients (see Apendix 1). Be-
cause of the variability of drugs employed we could not
analyze the reasons why different combinations were used,
but we can hypothesize the following reasons: 1) the inclu-
sion of patients began in 1990, before platinum-based chemo-
therapy came to be considered the standard of the care for
metastatic NSCLC patients; 2) some of the patients (49.6%)
came from public health system and this could create some
restrictions to the use of several regimens of chemotherapy;
3) in the period of 13 years different oncologists treated pa-
tients in the oncologic centers.
Due to the wide heterogeneity of chemotherapeutic regi-
mens employed to treat the patients included in the present
study, we expected that survival would be different from ob-
served in the published prospective randomized trials. How-
ever the overall median survival of our patient population
submitted to chemotherapy was 9.7 months. Schiller et al
studied four different regimens of platinum-based chemo-
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therapy for advanced NSCLC patients and observed that
there were no significant differences in survival between dif-
ferent regimens of chemotherapy, with median survival rang-
ing from 7.4 to 8.1 months among different combinations
of drugs5. In the last few years, other randomized clinical
trial disclosed equally poor survival for patients with ad-
vanced NSCLC treated with platinum-based chemotherapy,
with a median survival ranging from 8 to 10 months21. To
our surprise, the overall survival observed in the present study
is quite similar to that showed by prospective randomized
trials with adequate platinum-based chemotherapy. Many pa-
tients (19.4%) were lost from follow-up, as expected in a
retrospective population-based study. Moreover, staging
methods and images were not uniform among the centers
included in the present study, as opposed to strict randomized
trials. Both characteristics could explain, partially the sur-
vival rates observed in our study.
Irrespective to the regimen, there was a significant ad-
vantage for the group treated with chemotherapy as com-
pared to the group of patients that only received best sup-
portive care (Figure 2). However as a result of a
nonrandomized study this difference of survival might re-
flect a selection bias of patients with better prognosis to re-
ceive chemotherapy.
Despite the limitation of a retrospective review, this is
the first study to describe the widespread heterogeneity in
the management of metastatic NSCLC patients out of a
clinical trial, in the Brazilian population. This heterogene-
ity is mainly due to a great variability in combination of
chemotherapeutic regimens, some of them not tested in
randomized trials. Results of prospective randomized clini-
cal trials for metastatic NSCLC patients should be carefully
analyzed and transferred to the daily clinical practice ac-
cording to the reality of each center of oncologic treatment.
RESUMO
Naime FF, Younes RN, Kersten BG, Anelli A, Beato CAM,
Andrade RM, Carrara MP, Gross JL. Câncer de pulmão não
pequenas células metastático: Heterogeneidade do trata-
mento na prática clínica de rotina no Brasil. Clinics.
2007;62(4):397-404.
INTRODUÇÃO: O câncer de pulmão é uma das princi-
pais causas de morte relacionadas ao câncer. Aproximada-
mente três quartos destes tumores são carcinoma não pe-
quenas células. Ao diagnóstico, a maioria dos pacientes se
apresenta com doença avançada localmente ou metastática.
A quimioterapia é o tratamento de escolha para pacientes
com câncer de pulmão em estadiamento avançado. A mai-
oria dos estudos publicados com quimioterapia é realiza-
da em centros acadêmicos sob controle rígido de protoco-
los de pesquisa.
OBJETIVO: O objetivo deste estudo é avaliar os resultados
do tratamento rotineiro de pacientes com carcinoma de pul-
mão não pequenas células metastático, fora de protocolos de
pesquisa clínica em três centros oncológicos brasileiros.
MÉTODO: Trata-se de um estudo retrospectivo de paci-
entes com câncer de pulmão não pequenas células
metastático, admitidos para tratamento em três diferentes
centros oncológicos no Brasil. Foram avaliados 564 paci-
entes neste estudo provenientes do sistema de saúde pú-
blico e privado.
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RESULTADOS: Dentre os 564 pacientes deste estudo, 335
(59,4%) receberam quimioterapia. Considerando todos os
pacientes, foram identificados 47 esquemas diferentes de
quimioterapia. O tempo médio de seguimento foi de oito
meses e a sobrevida global mediana de todos os pacientes
submetidos à quimioterapia foi de 9,7 meses.
DISCUSSÃO: Havia uma grande heterogeneidade de es-
quemas de drogas para o tratamento de pacientes com cân-
cer de pulmão não pequenas células metastático. A
sobrevida global foi significativamente melhor para paci-
entes tratados com quimioterapia de primeira linha com-
parado com pacientes que receberam somente tratamento
de suporte clínico. Resultados de estudos clínicos
prospectivos randomizados deverão ser cuidadosamente
analisados antes de serem transferidos para a prática clíni-
ca diária.
UNITERMOS: Câncer de pulmão. Câncer de pulmão não
pequenas células (CPNPC). Metástases. Quimioterapia.
Prática clínica de rotina
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Appendix 1 – Different drug combinations employed to treat metastatic NSCLC.
Chemotherapy profiles IPC n 26 H C n 167 H Jaún 142 Total n 335 %
Cisplatin+doxorucicin+ciclofosfamide 1 0 37 38 11.3
Cisplatin+etoposide 1 12 22 35 10.4
Carboplatin+paclitaxel 6 23 3 32 9.6
Cisplatin+gemcitabine 2 9 21 32 9.6
MVP(mitomycin+vinblastine+cisplatin) 2 20 0 22 6.6
Cisplatin+vinorelbine 2 12 2 16 4.8
Carboplatin+etoposide 2 1 11 14 4.2
Paclitaxel+vinorelbine+carboplatin 0 14 0 14 4.2
Cisplatin+ifosfamide+vinblastine 0 11 0 11 3.3
Cisplatin+farmorubicina+ciclofosfamide 1 4 6 11 3.3
Cisplatin+5fluoruracil 0 0 10 10 3
Gemcitabine 0 9 1 10 3
Cisplatin+vinblastine 0 8 1 9 2.7
Gemcitabine+vinorelbine 3 4 0 7 2.1
Etoposide po 1 0 6 7 2.1
Docetaxel 0 6 0 6 1.8
Carboplatin+docetaxel 2 3 1 6 1.8
Vinorelbine 0 5 0 5 1.5
Mitomycin+vinblastine 0 3 1 4 1.2
Vincristin+doxorubicin+ciclofosfamide 0 4 0 4 1.2
Ciclofosfamide+etoposide 0 0 4 4 1.2
Chemotherapy profiles IPC n 26 H C n 167 H Jaún 142 No total n 335 %
Cisplatin+docetaxel 0 1 2 3 0.9
Gemcitabine+carboplatin 1 0 2 3 0.9
Ciclofosfamide+epirrubicina+vincristin 0 0 2 2 0.6
Cisplatin+paclitaxel 1 1 0 2 0.6
Vincristin+methotrexate+ciclofosfamide 0 2 0 2 0.6
Vincristin+etoposide 0 2 0 2 0.6
Cisplatin 0 1 1 2 0.6
Carboplatin weekly 0 1 1 2 0.6
Ciclofosfamide+methotrexate 0 2 0 2 0.6
Carboplatin+vinorelbine 0 2 0 2 0.6
Ifosfamide+carboplatin+vinblastine 0 1 0 1 0.3
Carboplatin+5fluoruracil 0 0 1 1 0.3
Carboplatin+ciclofosfamide+etoposide 0 1 0 1 0.3
Gemcitabine+docetaxel 1 0 0 1 0.3
Paclitaxel 0 1 0 1 0.3
Mitomycin+vinblastine+carboplatin 0 1 0 1 0.3
Fluoruracil+doxorubicin+ciclofosfamide 0 1 0 1 0.3
Methotrexate 0 1 0 1 0.3
Cisplatin+epirrubicin 0 0 1 1 0.3
Ciclofosfamide+epirrubicin 0 0 1 1 0.3
Carboplatin+ciclofosfamide 0 0 1 1 0.3
Chemotherapy profiles IPC n 26 H C n 167 H Jaún 142 No total n 335 %
Uft 0 0 1 1 0.3
Carboplatin+ciclofosfamide+vinblastine 0 0 1 1 0.3
Carboplatin+vinblastine 0 0 1 1 0.3
Gemcitabine+etoposide 0 0 1 1 0.3
Ifosfamide+mitexan+vinblastine 0 1 0 1 0.3
